TrialA Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Trial details
- Registry ID
- NCT05442775
- Phase
- Phase 3
Drug research
Reldesemtiv
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775 | Cytokinetics | Phase 3 | Terminated | 2023-06-07Actual |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784 | Cytokinetics | Phase 3 | Terminated | 2023-07-18Actual |
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Trial details
- Registry ID
- NCT04944784
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |